Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults
Antonio Rivero(University of Southern California), Josep M. Gatell(Hospital Clínic de Barcelona), Vicente Estrada(Instituto de Salud Carlos III), Rafael Rubio(Research Institute Hospital 12 de Octubre), Antonio Javier Blasco, Montserrat Tuset(Hospital Clínic de Barcelona), Rosario Palacios(Bellvitge University Hospital), Hernando Knobel(Hospital General de Granollers), José Ramón Arribas(Hospital Universitario La Paz), Juan A. Pineda(Hospital Universitario de Valme), Peré Domingo(Hospital de Sant Pau), Pablo Lázaro(Madrid Health Service), Fernando Lozano(Hospital Universitario de Valme), Santiago Moreno(Universidad El Bosque), Manuel Crespo(Vall d'Hebron Hospital Universitari), José Antonio Iribarren(Biogipuzkoa Health Research Institute), Federico Pulido(Bellvitge University Hospital), José López-Aldeguer(Apple (Israel)), José A. Pérez‐Molina(Instituto de Salud Carlos III)
Cited by 22
Related Papers
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
|The Lancet. Gastroenterology & hepatology|2016|2k
Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV
|New England Journal of Medicine|2006|886